GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » ROCE %

Fresh2 Group (Fresh2 Group) ROCE % : 0.00% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fresh2 Group's annualized ROCE % for the quarter that ended in Jun. 2023 was 0.00%.


Fresh2 Group ROCE % Historical Data

The historical data trend for Fresh2 Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group ROCE % Chart

Fresh2 Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial -1,151.38 - - -2,170.23 -6,556.18

Fresh2 Group Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -413.11 94.56 -1,432.46 -3,062.82 -

Fresh2 Group ROCE % Calculation

Fresh2 Group's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-15.112/( ( (10.596 - 9.876) + (5.805 - 6.064) )/ 2 )
=-15.112/( (0.72+-0.259)/ 2 )
=-15.112/0.2305
=-6,556.18 %

Fresh2 Group's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2023 )  (Q: Dec. 2022 )(Q: Jun. 2023 )
=0/( ( (5.805 - 6.064) + (24.885 - 8.355) )/ 2 )
=0/( ( -0.259 + 16.53 )/ 2 )
=0/8.1355
=0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh2 Group  (NAS:FRES) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Fresh2 Group ROCE % Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh2 Group (Fresh2 Group) Business Description

Traded in Other Exchanges
Address
650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.